MiNK TherapeuticsINKT
INKT
About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Employees: 23
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.46% less ownership
Funds ownership: 2.04% [Q4 2024] → 1.59% (-0.46%) [Q1 2025]
4% less capital invested
Capital invested by funds: $565K [Q4 2024] → $544K (-$20.7K) [Q1 2025]
26% less funds holding
Funds holding: 23 [Q4 2024] → 17 (-6) [Q1 2025]
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 15
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$35
383%
upside
Avg. target
$35
383%
upside
High target
$35
383%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar | 383%upside $35 | Buy Reiterated | 18 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
Neutral
GlobeNewsWire
1 week ago
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings
Neutral
Seeking Alpha
1 month ago
MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Zack Armen - IR Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Thiago Favano - Senior Director, Portfolio Operations Conference Call Participants Emily Bodnar - H.C. Wainwright Matt Phipps - William Blair Operator Thank you for standing by.
Neutral
GlobeNewsWire
1 month ago
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its iNKT platform. The company will host a conference call and webcast today at 8:30 a.m. ET.
Neutral
GlobeNewsWire
1 month ago
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Neutral
Seeking Alpha
2 months ago
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2024 Earnings Conference Call March 18, 2025 8:30 AM ET Company Participants Zack Armen - Investor Relations Dr. Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Neutral
GlobeNewsWire
2 months ago
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET.
Neutral
GlobeNewsWire
3 months ago
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Neutral
GlobeNewsWire
3 months ago
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers
Neutral
GlobeNewsWire
4 months ago
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (NCT06251973).
Charts implemented using Lightweight Charts™